Partnering with Governments to Prepare for Future Pandemics We have long been a trusted partner for governments worldwide, helping them meet community needs and quickly respond to future pandemics or outbreaks. We are currently a pandemic and outbreak partner with over 30 governments globally. Through these partnerships, we support governments and public health agencies in the U.S., EU, UK and beyond by delivering pre-pandemic vaccines and adjuvant (substances that help vaccines work more effectively) stockpiles. As of June 2025, CSL and its predecessor companies have contributed $57.2 million to the World Health Organization’s (WHO’s) Pandemic Influenza Preparedness (PIP) Framework. PIP brings together governments, industry and the WHO to implement a global approach to pandemic influenza preparedness and response. It aims to improve the sharing of information on influenza viruses with pandemic potential and the equitable access to products necessary to respond to an influenza pandemic including vaccines, antivirals and diagnostics. Antivenoms Approximately 3,000 Australians are hospitalised due to contact with a venomous creature in Australia every year. As the only manufacturer in the world to supply antivenoms for venomous creatures native to Australia, we serve a significant public health need. We are the sole provider of a unique range of products made in the national interest for the Australian government, including antivenoms and Q fever vaccine. We also contribute to programs that help raise awareness and educate communities about venomous bites and stings in the Asia Pacific region. $57.2m contributed to the World Health Organization’s Pandemic Influenza Preparedness Framework The PNG Snakebite Partnership Papua New Guinea (PNG) has historically had one of the highest rates of snakebite death in the world. It’s estimated there are more than 1,000 deaths a year due to snakebites in PNG, with nearly half of all fatalities involving children. PNG has many of the same venomous snakes that are found in Australia. Through our partnership with the Australian government, PNG’s National Department of Health and St John Ambulance PNG, we provide an annual donation of up to 600 vials of Australian-made antivenom to PNG. St John Ambulance distributes the antivenoms to more than 65 healthcare clinics through PNG, trains healthcare workers in snakebite patient management, and collects epidemiological data to improve local snakebite care. Since 2018, the partnership has helped save over 2,500 lives, provided almost 3,500 doses of antivenoms for venomous snakes and marine creatures, and delivered training to 2,300 healthcare workers, creating an enduring patient impact. In addition to an annual financial contribution, we have also committed 10% of influenza vaccine output in real time to the WHO for deployment to lower-middle income countries in the event of a pandemic emergency. Our partnerships also extend to academic bodies like the Pandemic Institute in Liverpool. We are halfway through a five year partnership and are collaborating on projects aimed at addressing vaccine hesitancy in underserved communities, enhancing manufacturing processes, and leveraging AI to model avian influenza. These efforts are particularly crucial given the global concern about highly pathogenic avian influenza (HPAI) in wild bird populations. Improving Vaccine Effectiveness Influenza viruses constantly change through a process called antigenic drift, which allows them to evade the immune system. Occasionally, two viruses can exchange genetic material in a process called reassortment. Each year, the WHO monitors global influenza activity and recommends which influenza virus strains should be included in seasonal vaccines. For decades, we have worked with our partners in Liverpool and Melbourne on the responsible development of vaccine seed strains and reassortants, helping to ensure the effectiveness of influenza vaccines worldwide. CSL Seqirus has pioneered the use of cell-based seed strains, which avoid the changes that can occur when viruses are grown in eggs. This means vaccines are a closer match to the circulating influenza viruses, offering people greater protection, and allowing faster, more reliable vaccine production – especially important during a pandemic. St John Ambulance PNG staff following the training of healthcare workers in snakebite envenomation management. 17 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Science and Medicine Legacy Healthier Communities
RkJQdWJsaXNoZXIy MjE2NDg3